Flávio Augusto Cardoso Faria

Flávio Augusto Cardoso Faria

Auto-generated profile, based on publicly available information

Flávio Augusto Cardoso Faria

Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Closed access
YCYuri Martins Costa
Yuri Martins Costa
PCPaulo César Rodrigucs Conti
Paulo César Rodrigucs Conti
FFFlavio Augusto Cardoso de Faria
Flavio Augusto Cardoso de Faria
LBLeonardo Rigoldi Bonjardim
Leonardo Rigoldi Bonjardim

5 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CSCarlos F. Santos
Carlos F. Santos
AMAna Carolina Morandini
Ana Carolina Morandini
TDThiago J. Dionísio
Thiago J. Dionísio
FFFlávio A. Faria
Flávio A. Faria
MLMarta C. Lima
Marta C. Lima
AGAndrew S. Greene
Andrew S. Greene
The initiation or progression of periodontitis might involve a local renin-angiotensin system (RAS) in periodontal tissue. The aim of this study was to further characterize the local RAS in human and rat periodontal tissues between healthy and periodontally-affected tissue. Components of the RAS were investigated using in vitro, ex vivo and in vivo experiments involving both human and Wistar rat periodontium. Although not upregulated when challenged with P. gingivalis-lipopolysaccharide, human gingival and periodontal ligament fibroblasts expressed RAS components. Likewise, healthy and inflamed human gingiva expressed RAS components, some of which were shown to be functional, yet no differences in expression were found between healthy and diseased gingiva. However, in inflamed tissue the immunoreactivity was greater for the AT1R compared to AT2R in fibroblasts. When compared to healthy tissue, ACE activity was increased in human gingiva from volunteers with gingivitis. Human-gingiva homogenates generated Ang II, Ang 1-9 and Ang 1-7 when incubated with precursors. In gingiva homogenates, Ang II formation from Ang I was nearly abolished only when captopril and chymostatin were combined. Ang 1-7 formation was significantly greater when human gingiva homogenates were incubated with chymostatin alone compared to incubation without any inhibitor, only captopril, or captopril and chymostatin. In rat gingiva, RAS components were also found; their expression was not different between healthy and experimentally induced periodontitis (EP) groups. However, renin inhibition (aliskiren) and an AT1R antagonist (losartan) significantly blocked EP-alveolar-bone loss in rats. Collectively, these data are consistent with the hypothesis that a local RAS system is not only present but is also functional in both human and rat periodontal tissue. Furthermore, blocking AT1R and renin can significantly prevent periodontal bone loss induced by EP in rats.

1 December 2007 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
CSCarlos F. Santos
Carlos F. Santos
KMKarin C.S. Modena
Karin C.S. Modena
FGFernando P.M. Giglio
Fernando P.M. Giglio
VSVivien T. Sakai
Vivien T. Sakai
ACAdriana Maria Calvo
Adriana Maria Calvo
JLJosé R.P. Lauris
José R.P. Lauris

1 July 2008 in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Verified
Journal Article
Closed access
LGLeonardo V.L. Gregorio
Leonardo V.L. Gregorio
FGFernando P.M. Giglio
Fernando P.M. Giglio
VSVivien T. Sakai
Vivien T. Sakai
KMKarin C.S. Modena
Karin C.S. Modena
BCBella L. Colombini
Bella L. Colombini
CSCarlos F. Santos
Carlos F. Santos

1 January 2007 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
ACAdriana Maria Calvo
Adriana Maria Calvo
VSV.T. Sakai
V.T. Sakai
FGF.P.M. Giglio
F.P.M. Giglio
KMK.C.S. Modena
K.C.S. Modena
BCB.L. Colombini
B.L. Colombini
CSCarlos F. Santos
Carlos F. Santos

22 July 2015 in Journal of Dental Research
Verified
Journal Article
Closed access
PDF file
ASA.M. Senes
A.M. Senes
ACAdriana Maria Calvo
Adriana Maria Calvo
BCB.L. Colombini-Ishikiriama
B.L. Colombini-Ishikiriama
PGP.Z. Gonçalves
P.Z. Gonçalves
TDThiago J. Dionísio
Thiago J. Dionísio
CSCarlos F. Santos
Carlos F. Santos
This double-blind crossover randomized clinical trial compared the efficacy of 2 concentrations of articaine, 2% (A2) and 4% (A4), with 1:200,000 epinephrine, for lower third molar removal. During 2 separate appointments with either A2 or A4, both similarly positioned lower third molars in 46 volunteers were extracted. The following were evaluated: onset and duration of anesthetic action on soft tissues, intraoperative bleeding, hemodynamic parameters, postoperative analgesia, and mouth opening and wound healing during the 7th postoperative day, along with the incidence, type, and severity of adverse reactions. Nearly identical volumes of both anesthetic solutions were used for each appointment: 3.4 ± 0.9 mL ≈ 68 mg of articaine (A2) and 3.3 ± 0.8 mL ≈ 132 mg of articaine (A4). Statistical analysis indicated no differences in onset or duration of anesthetic action on soft tissues or duration of postoperative analgesia evoked by A2 and A4 anesthetic solutions (P > 0.05). The surgeon’s rating of intraoperative bleeding was considered minimal throughout all surgery with both anesthetic solutions. While transient changes in blood pressure, heart rate, and oxygen saturation were observed, these factors were clinically insignificant and were uninfluenced by articaine concentration (P > 0.05). No systemic or local adverse reactions were observed in the preoperative and postoperative periods due to A2 or A4, but 1 case of bilateral paresthesia was observed. There were no significant differences between preoperative and postoperative (7th day) values of mouth opening and wound healing whether volunteers received A2 or A4 (P > 0.05). In conclusion, both A2 and A4, administered in equal volumes, were effective and safe during lower third molar surgery, and no significant differences were found between their efficacy and safety (ClinicalTrials.gov NCT02457325).